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Abstract
Purpose We evaluated whether synovial fluid (SF) leptin
concentrations correlate with pain severity in patients with
hip or knee endstage osteoarthritis (OA) and whether they
mediate the association between increased joint pain and (1)
female gender and (2) obesity.
Methods We conducted a cross-sectional study including
patients with primary hip and knee OA undergoing joint
replacement between January and December 2010. SF leptin
concentrations obtained on the day of surgery were assessed.
Main outcome was pain severity measured pre-operatively
using WOMAC and VAS pain scales.
Results A total of 219 patients were included, 123 hip and 96
knee arthroplasties. Mean age was 72 years, 59 %were women.
Mean SF leptin levels were 22.9 (±25.6) ng/ml in women and
5.4 (±5.9) ng/ml in men. Levels >19.6 ng/ml (highest quartile)
were significantly associated with increased pain on both
WOMAC (mean difference −9.6, 95 % CI −15.1 to −4.0) and
VAS scale (mean difference 0.8, 95 %CI 0.2–1.3). Associations
remained unchanged after adjusting for age, co-morbidities,
contra-lateral arthritic joint, OA site, and disability. The
associations observed between increased pain and female gen-
der or obesity were substantially reduced after adjusting for SF
leptin.
Conclusion Joint pain is associated with SF leptin concen-
trations. Increased pre-operative pain observed in women
and obese may be related to high intra-articular leptin levels.
Introduction
Joint pain is the key clinical feature of osteoarthritis (OA)
[1–3] and plays a major role in the decision for a total joint
arthroplasty, but the causes of OA pain are not well
established [4] and correlation between pain and structural
joint damage is weak [5]. A possible link between joint pain
and the adipokine leptin, which is considered as a key medi-
ator in the well established association between obesity and
osteoarthritis (OA) [6–13], has been indirectly suggested in
studies on weight loss. Weight reduction consistently resulted
in decreased joint pain in patients with OA [14, 15] and
simultaneously decreased blood leptin levels [16–18]. Fur-
thermore, leptin is particularly elevated in women and in
obese patients [10, 19], and in these two patient groups, higher
OA pain levels have been reported [20–26]. Studies from
outside the musculoskeletal field have lent further support to
a possible association between pain and leptin concentrations.
Leptin levels in peritoneal fluid correlated positively with pain
severity in endometriosis patients [27]. Furthermore, recent
studies in rodents [28–30] suggested that spinal leptin might
be involved in the pathogenesis of neuropathic pain.
So far two clinical studies have evaluated the association
between adipokines and OA pain. Gandhi et al. [31] did not
find a clear association between intra-articular leptin concen-
trations and pre-operative pain, but they reported that the
synovial fluid (SF) adiponectin/leptin ratio predicted pain.
Massengale et al. [32] showed that leptin serum concentration
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was associated with the intensity of pain in patients with
chronic hand OA.
The objective of this study was to investigate if leptin may
influence joint pain in OA patients. We hypothesized that SF
leptin concentrations correlate with pain severity, and medi-
ate the association between joint pain and (1) female gender
and (2) obesity.
Materials and methods
Study design and patient population
We conducted a cross-sectional study including patients with
end-stage OA of the hip and knee who presented for a total
joint arthroplasty at a large orthopaedic centre between Jan-
uary and December 2010. Only patients with primary hip or
knee OAwere eligible. The study was approved by the local
ethics committee and informed consent was obtained from
all patients. Overall, synovial fluid (SF) was collected from
250 patients. Of those 219 had completed the pain scores and
they were included in the final analysis.
Exposures of interest
Exposure of interest was the intra-articular (SF) concentration
of leptin obtained at the time of joint replacement surgery (hip
or knee). It was measured by a sandwich ELISA technique
using the DuoSet ELISA Development Systems (R&D Sys-
tems, Abingdon, UK) according to the manufacturer’s proto-
cols. The minimum detectable cytokine concentration for
these assays was estimated to be 31 pg/ml for leptin.
Sex and body mass index (BMI) were the clinical factors of
interest. BMI was analysed as continuous and dichotomised
variable (BMI<30 kg/m2 = non-obese vs. ≥ 30 kg/m2 = obese).
Outcome of interest
One outcome of interest was the pre-operative pain level mea-
sured with the Western Ontario McMaster Universities Osteoar-
thritis Index (WOMAC) pain score [33]. We employed the 5-
point Likert scale version of the WOMAC 3.0. We analysed the
score both as continuous (0–100, 100 = no pain) and as dichot-
omized variable (> 25 vs. ≤ 25 = quartile with greatest pain). We
also used the visual analog scale (VAS) for pain assessment. The
scale was evaluated as continuous (0–10, 0 = no pain) and as a
dichotomized variable (< 7 vs. ≥ 8 = quartile with greatest pain).
Both patient-assessed instruments are validated and widely used.
In addition, the physician assessed pain item of the Harris hip
score (HHS) (0–44, 44 = no pain) [34] was evaluated in patients
with hip OA, and the physician-assessed pain item of the Amer-
ican Knee Society score (AKSS) (0–50, 50 = no pain) [35] was
evaluated in patients with knee OA.
Co-variates and potential confounders
The following variables were assessed: (a) age; (b) American
Society of Anesthesiologists (ASA) score investigated as
binary variable (ASA<3 vs. ≥ 3); (c) OA site (hip vs. knee);
(d) presence of diabetes; (e) Medical Outcomes Study Short
Form-12 (SF-12), a patient-administered generic health-
related quality of life measure comprising a mental (mcs)
and physical component score (pcs) [36]; the summary mea-
sures range from 0 to 100 (100 = best); (f) presence of a
contra-lateral arthritic or operated joint; (g) Charnley disability
category C for the hip and AKSS disability category C for the
knee; the category C is defined as presence of multiple joint
disease or other disabilities leading to difficulties in ambu-
lation [35, 37]; (h) radiological severity of OA (Kellgren-
Lawrence grades 0–4 and presence of osteophytes, subchondral
sclerosis and minimal joint space width [minJSW]) [38]; (i)
serum (blood) leptin concentration in ng/ml; and (j) synovial
fluid adiponectin concentration in μg/ml.
Data collection
Synovial fluid (1 ml) was taken during the intervention by
the operating surgeon by direct aspiration through the joint
capsule, after skin incision, in order to minimize blood
contamination. Blood samples (5 ml) were obtained during
the pre-operative examination, at the same time as the pre-
operative blood draw. A medical secretary was responsible
for SF and blood sample transport. Patients’ samples were
made anonymous prior to transport to the laboratory. All
blood and SF samples were immediately centrifuged,
aliquoted and frozen at −80 °C, until they were measured.
Since 1996 all patients undergoing total hip arthroplasty
(THA) and since 1998 all those undergoing total knee
arthroplasty (TKA) in the Geneva University Hospitals have
been routinely enrolled in a prospective hospital-based co-
hort. The patients included in this study are part of the
two cohorts. Information about baseline characteristics
including medical and orthopaedic co-morbidities is rou-
tinely documented on specifically designed data collec-
tion forms. Pre-operative score and questionnaire assess-
ment is routinely performed for all patients undergoing
joint arthroplasty surgery. Harris hip score in case of
hip OA and AKSS score in knee OA were assessed by
the orthopaedic surgeon in charge of the patient the day
before surgery. The WOMAC and the SF-12 were sent to
all patients seven to ten days prior to surgery. The medical
secretary was involved in sending and collecting scores and
questionnaires and in data entry. The assessment of the radio-
graphic severity of OA and identification of specific OA fea-
tures was performed on pre-operative radiographs by two or-
thopaedic surgeons (GP, DS) blinded to the patient’s laboratory
and clinical results.
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Statistical analysis
The distribution of leptin concentrations (synovial fluid and
serum) was right-skewed. To allow for comparison with
previous literature on leptin and OA, we reported both mean
(standard deviation, ± SD) and median (interquartile range,
IQR) concentrations.
The association between SF leptin and preoperative pain
levels was evaluated (1) as continuous variable using the
Spearman’s correlation coefficient and (2) as categorical variable
using quartiles. In particular, we compared pain levels in the 4th
quartile (> 19.6 ng/ml) to those in the combined 1st to 3rd
quartiles (≤ 19.6 ng/ml). First, we evaluated the percentage of
patients with severe pain (defined as WOMAC ≤ 25 and VAS ≥
Table 1 Pre-operative patient characteristics and radiological features according to leptin concentration (in quartiles) in synovial fluid
Characteristic Leptin 1st quartile
(n=56) ≤ 3.0 ng/ml
Leptin 2nd quartile
(n=54) 3.01–8.7 ng/ml
Leptin 3rd quartile
(n=56) 8.71–19.6 ng/ml
Leptin 4th quartile
(n=53)>19.6 ng/ml
p–valuea
Men (%) 39 (69.6) 34 (63.0) 13 (23.2) 3 (5.7) <0.001
Women (%) 17 (30.4) 20 (37.0) 43 (76.8) 50 (94.3)
Hip OA (%) 31 (55.4) 36 (66.7) 33 (58.9) 23 (43.4) 0.160
Knee OA (%) 25 (44.6) 18 (33.3) 23 (41.1) 30 (56.6)
BMI ≥ 30 kg/m2 (%) 4 (7.1) 11 (20.4) 15 (26.8) 31 (58.5) <0.001
Diabetes (%) 9 (16.1) 9 (16.7) 8 (14.3) 2 (3.8) 0.056
ASA score 3–4 (%) 9 (16.1) 10 (18.5) 8 (14.3) 12 (22.6) 0.515
Contra-lateral joint
arthritic (%)
28 (50.0) 28 (51.9) 29 (51.8) 35 (66.0) 0.117
Disability category C (%)b 14 (25.0) 17 (31.5) 22 (39.3) 20 (37.7) 0.104
Age, mean, SD 72.5 (±9.1) 71.6 (±9.4) 72.3 (±9.3) 70.9 (±8.2) 0.448
BMI, mean, SD 24.6 (±3.5) 27.6 (±4.0) 27.9 (±3.6) 31.9 (±5.3) <0.001
SF-12 mcs, mean, SD 46.7 (±10.6) 42.6 (±12.1) 42.8 (±11.0) 39.6 (±10.6) 0.002
SF-12 pcs, mean, SD 35.6 (±8.6) 33.8 (±8.4) 35.0 (±8.2) 30.9 (±6.3) 0.010
Leptin serum, median, IQR 3.7 (2.0–5.3) 10.5 (6.5–16.0) 23.9 (15.6–34.3) 57.1 (36.9–82.2)
Adiponectin (µg/ml), SF,
median, IQR
0.2 (0.1–0.6) 0.3 (0.1–0.7) 0.3 (0.2–0.6) 0.4 (0.1–0.7)
Radiological features Leptin 1st quartile
≤ 3.0 ng/ml
Leptin 2nd quartile
3.01–8.7 ng/ml
Leptin 3rd quartile
8.71–19.6 ng/ml
Leptin 4th quartile>
19.6 ng/ml
p-valuea
Hip OA group n=31 n=35 n=30 n=22
Kellgren-Lawrence (%)
2 2 (6.5) 3 (8.6) 7 (23.3) 3 (13.6) 0.343
3 12 (38.7) 10 (28.6) 9 (30.0) 6 (27.3)
4 17 (54.8) 22 (62.9) 14 (46.7) 13 (59.1)
Osteophytes (%)
Acetabular 25 (80.6) 30 (85.7) 25 (83.3) 13 (59.1) 0.096
Femoral 22 (71.0) 30 (85.7) 23 (76.7) 14 (63.6) 0.492
Subchondral sclerosis (%) 25 (80.6) 30 (85.7) 22 (73.3) 14 (63.6) 0.094
Minimal JSW, mm (SD) 0.96 (±1.1) 0.91 (±1.2) 1.28 (±1.4) 0.79 (±1.2) 0.979
Knee OA group n=24 n=18 n=21 n=30
Kellgren-Lawrence (%)
2 1 (4.2) – 1 (4.8) 1 (3.3) 0.825
3 10 (41.7) 10 (55.6) 10 (47.6) 12 (40.0)
4 13 (54.2) 8 (44.4) 10 (47.6) 17 (56.7)
Osteophytes (%)
Femoral 19 (79.2) 17 (94.4) 20 (95.2) 27 (90.0) 0.245
Tibial 22 (91.7) 18 (100.0) 20 (95.2) 26 (86.7) 0.370
Subchondral sclerosis (%) 19 (79.2) 16 (88.9) 20 (95.2) 26 (86.7) 0.383
Minimal JSW, mm (SD) 1.37 (±1.0) 1.50 (±0.9) 1.58 (±1.1) 1.35 (±1.4) 0.943
SF-12 mcs SF-12 mental health component score, SF-12 pcs physical health component score, IQR interquartile range, SF synovial fluid
a p-value for linear trend obtained with chi-square linear trend test for categorical variables and with ANOVA test for linearity for continuous
variables
b Charnley/AKSS disability category C (multiple joint disease or other disabilities leading to difficulties in ambulation)
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8) in the various leptin categories and computed relative risks
(RR) of severe pain by leptin category. Second, we calculated
mean pain score differences using linear regression analysis.
Because differences in pain levels could be related to
other factors (confounding factors), we adjusted the anal-
ysis for age, diabetes, ASA score, contra-lateral arthritic
joint, OA site and disability category C. In a second model
we additionally adjusted for the SF-12 mental component
score. This was done to separately show the influence of
mediating psychological factors (mental health) on pain
expression. We first analysed the data separately in patients
with hip and knee OA, but decided the priority was to com-
bine the results in the absence of effect modification by OA
joint. Baseline characteristics are presented according to leptin
quartiles.
In the second study objective, we explored whether leptin
could mediate the association between pain and (1) female
gender and (2) obesity in patients with OA. We first assessed
crude pain differences by gender and by BMI categories and
then we examined if adjusting for SF leptin concentration in
Fig. 1 Proportion of patients
with WOMAC pain scores ≤ 25
(highest pain levels) according to
intra-articular leptin
concentration (in quartiles)
Fig. 2 Proportion of patients
with VAS pain scores ≥
8 (highest pain levels) according
to intra-articular leptin
concentration (in quartiles)
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a multivariate regression model would mitigate these univar-
iate associations.
Results
Overall, 219 patients were evaluated, 123 with hip (56.2 %)
and 96 with knee OA. Mean age was 72 (±9) years, and 59 %
were women (n=130). Mean BMI was 28.0 (±4.9) kg/m2,
27.3 kg/m2 in the hip group and 29.1 kg/m2 in the knee
group. The median SF leptin concentration was 8.7 (IQR
3.0, 19.6) ng/ml and the mean concentration 15.8 (±21.8)
ng/ml. In addition, mean SF leptin concentrations were 22.9
(±25.6) ng/ml in women compared to 5.4 (±5.9) ng/ml in
men, and they were 12.4 (± 15.6) ng/ml in patients with hip
OA compared to 20.1 (± 27.2) ng/ml in those with knee OA.
SF leptin concentrations were divided into quartiles with
the highest quartile corresponding to levels>19.6 ng/ml. The
proportion of women increased strongly with rising leptin
levels, up to 94 % in the highest quartile (Table 1). Similar
results were seen for obesity, with the greatest proportion
(59 %) of obese patients in the highest quartile. In addition,
patients in the highest leptin category had less often diabetes,
and more often knee OA, a contralateral arthritic joint, as
well as an ASA score of 3–4. The SF-12 mcs and pcs scores
were the lowest in this group. The radiographic severity of
hip and knee OA did not differ substantially according to SF
leptin quartiles (Table 1).
Synovial fluid leptin and pain
There was a weak correlation between SF leptin concentra-
tions (continuous) andWOMAC pain (Spearman’s correlation
coefficient r=−0.182) as well as between leptin and VAS pain
(r=0.115). Patients with high SF leptin concentrations
(highest quartile: >19.6 ng/ml) reported higher pain levels
on both the WOMAC and VAS pain scales. In the highest
leptin quartile, 45 % of patients had a WOMAC pain score ≤
25 compared to 20 % in the other quartiles (RR 2.3, 95 % CI
1.5; 3.5), and 42 % had a VAS pain score ≥ 8 compared to
21 % in the other quartiles (RR 2.0, 95 % CI 1.3–3.0) (Figs. 1
and 2). This association between SF leptin levels and pain
(shown for WOMAC as percentage of patients ≤ 25; highest
quartile vs. others) was apparent both in women (46 vs. 21 %)
and men (33 vs. 19 %), obese (45 vs. 23 %) and non-obese
patients (46 vs. 19 %), and in hip (57 vs. 24 %) and knee OA
patients (37 vs. 14 %) (Figs. 3, 4 and 5).
Fig. 3 Proportion of WOMAC pain scores ≤ 25 in women and men
according to intra-articular leptin concentration (highest quartile
[leptin>19.6 ng/ml] vs. all other quartiles [≤19.6 ng/ml])
Fig. 4 Proportion ofWOMAC pain scores ≤ 25 in obese and non-obese
patients according to intra-articular leptin concentration (highest quar-
tile [leptin>19.6 ng/ml] vs. all other quartiles [≤19.6 ng/ml])
Fig. 5 Proportion of WOMAC pain scores ≤ 25 in patients with hip and
knee osteoarthritis according to intra-articular leptin concentration
(highest quartile [leptin>19.6 ng/ml] vs. all other quartiles [≤19.6 ng/ml])
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The unadjusted mean score difference between patients in the
highest leptin quartile compared to those in the other quartiles
was −9.6 (95%CI −15.1; −4.0; standardized effect size 0.54) for
the WOMAC and 0.8 (95 % CI 0.2; 1.3; standardized effect size
0.44) for the VAS (Table 2). The association remained virtually
unchanged after adjusting for potential confounders such as age,
ASA score, contra-lateral arthritic joint, OA site, disability cate-
gory C and diabetes (WOMAC adjusted mean difference −9.1
[95 % CI −14.8 to −3.5] and VAS adjusted mean difference 0.7
[95 % CI 0.2–1.3]). Additional adjustment for the SF-12 mental
component score (WOMAC adjusted mean difference −6.8
(95 % CI −12.2 to −1.3) and VAS adjusted mean difference
0.6 [95 % CI 0–1.2]) slightly lowered the estimates, but the
association remained significant. A greater degree of pain was
seen in patients with high leptin levels as assessed by both the
patient-assessed and the joint-specific physician-assessed scores
HHS and AKSS (Table 2).
Significant associations between increased joint pain as
measured with WOMAC and (1) female gender and (2)
obesity observed in univariate analyses were substantially
reduced after adjusting for SF leptin concentrations. Themean
difference in WOMAC for women vs. men decreased from
4.7 to 1.6 and from 7.0 to 4.1 for obese vs. non-obese after
correcting for leptin concentrations, suggesting that these
associations might partially be mediated by leptin (Table 3).
Correlation with serum leptin
Synovial fluid leptin levels strongly correlated with serum leptin
levels (correlation coefficient r=0.875). Overall, the median
serum leptin concentration was 15.8 (IQR 5.7, 36.9) ng/ml and
the mean concentration 27.9 (±34.3) ng/ml. In addition, mean
serum leptin concentrations were 38.7 (±39.5) ng/ml in women
compared to 11.6 (±13.2) ng/ml in men.
Discussion
We found that OA patients with high SF leptin concentra-
tions reported substantially more OA pain. Furthermore, the
Table 2 Pre-operative pain levels according to leptin concentrations in synovial fluid
Score Leptin 1–3rd
quartile ≤ 19.6
ng/ml
Leptin 4th
quartile > 19.6
ng/ml
4th vs. 1–3rd unadjusted
mean difference
(95 % CI)
4th vs. 1–3rd adjusted
mean difference
(95 % CI)b
4th vs. 1–3rd adjusted
mean difference
(95 % CI)c
All (n=219)a n=166 n=53
WOMAC 41.4 (±18.5) 31.8 (±15.5) −9.6 (−15.1; −4.0) −9.1 (−14.8; −3.5) −6.8 (−12.2: −1.3)
VAS 5.8 (±1.8) 6.6 (±1.8) 0.8 (0.2; 1.3) 0.7 (0.2; 1.3) 0.6 (0; 1.2)
Hip (n=123) n=100 n=23
WOMAC 39.8 (±19.2) 28.0 (±16.8) −11.8 (−3.2; −20.4)
VAS 6.0 (±1.8) 6.8 (±2.0) 0.7 (−0.1; 1.6)
HHS 16.8 (±10.0) 14.4 (±7.9) −2.4 (−6.9; 2.0)
Knee (n=96) n=66 n=30
WOMAC 43.8 (±17.3) 34.8 (±14.0) −9.0 (−1.9; −16.2)
VAS 5.5 (±1.7) 6.4 (±1.5) 0.9 (0.2; 1.6)
AKSS 16.5 (±11.1) 13.7 (±8.8) −2.8 (−7.7; 2.0)
a Values presented are means and standard deviations
b Adjusted for age, diabetes, ASA score, contra-lateral arthritic joint and disability category C (multiple joint disease or other disabilities leading to
difficulties in ambulation)
c Adjusted for age, diabetes, ASA score and contra-lateral arthritic joint, disability category C and SF-12 mental component score
Table 3 Association between
WOMAC pain and (1) sex and
(2) body mass index
Group WOMAC
pain mean (SD)
Mean difference
unadjusted (95 % CI)
p-value Mean difference
adjusted for leptin
(95 % CI)
p-value
Women 37.2 (±18.8)
Men 41.9 (±17.2) −4.7 (−9.6; 0.2) 0.062 −1.6 (−6.9; 3.7) 0.556
Obese 34.1 (±14.6)
Non-obese 41.1 (±19.2) −7.0 (−12.3; −1.6) 0.011 −4.1 (−9.8; 1.7) 0.165
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increased levels of pain observed in women and in obese
patients seemed to be associated with high intra-articular
leptin concentrations. However, due to the cross-sectional
design a causal relation between leptin and pain cannot be
ascertained.
Pain is certainly the most important symptom of OA, but
also the least well understood [39]. Recent models imply that
OA pain consists of a nociceptive stimulation of the joint and
of peripheral sensitization, which can be accompanied by
spinal and central sensitization [2, 40–43]. Leptin may affect
the OA pain response in at least two possible ways. First,
leptin appears to be a mediator of the immuno-inflammatory
response in different experimental models. The pro-
inflammatory cytokine-like functions of leptin in OA [10,
44–47] could explain its role in peripheral sensitization.
Second, animal models suggest an involvement of leptin in
the pathogenesis of pain at the spinal level and a possible role
in the development of neuropathic pain [28–30]. Our clinical
results support these experimental findings in patients with
lower limb OA.
Our findings are in accordance with Massengale et al. [32]
who, in a cohort of patients with chronic hand OA, reported
an association between serum leptin levels with pain inten-
sity but not with radiographic severity. Ghandi et al. [31]
have investigated the relation between leptin and pain. They
did not find a clear association between intra-articular leptin
concentrations and pain in a linear regression analysis, but
reported that the synovial fluid (SF) adiponectin/leptin ratio
predicted pain. We found that the association between intra-
articular leptin concentration and pain intensity was not
linear. Pain intensity was similar within the lower three
quartiles, but substantially higher in the highest quartile of
leptin concentration.
Clinical implications of these findings might be: (1) exer-
cise and weight loss programs should be particularly targeted
to women, who constitute the vast majority of the high leptin
level group; and (2) prospective studies are warranted to test
the clinical usefulness of serum leptin as a biomarker (as a
proxy for intra-articular leptin level) to identify subgroups of
patients, who would particularly benefit from exercise and
weight loss programs, to detect the presence of neuropathic
pain reported to be common in knee OA patients [48, 49], as
well as to predict persistence of pain after total joint
arthroplasty.
The main limitation of this analysis is its cross-sectional
design, and therefore the study is not suited to establish a
causal link between leptin and increased pain. Leptin is a
pleiotropic cytokine with central and peripheral effects in-
volved in the regulation of energy intake and expenditure, of
bone metabolism and inflammatory responses as well as of
stress response [50]. Despite the above mentioned evidence
from experimental studies supporting a possible causal effect
of leptin on pain, other explanations for our findings including
inverse causation and residual confounding need to be ex-
plored in future studies.
Second, we evaluated pain with two widely used, patient-
assessed validated instruments. Because physician evalua-
tion of pain has been found to be less influenced by the
presence of co-morbidities [51], we additionally included
one hip- and one knee-specific physician-assessed pain
sub-score. However, information about the quality of pain
(pain on movement, pain on rest, morning stiffness) was not
routinely recorded. Third, depression and comorbidities, in
particular the presence of OA at multiple sites, have been
identified as important factors influencing the perception and
severity of pain [20, 52–54].
A depression-specific instrument was not used in our
study, but we collected information on mental health status
using the SF-12 mental component score. Moreover, specific
information about OA in other joints except for the contra-
lateral joint was not systematically available. However, we
assessed (and adjusted for) the presence of multiple joint
disease and other medical disabilities leading to difficulties
in ambulation.
Conclusion
Our results suggest that high leptin concentrations may affect
the level of joint pain in OA of the lower limbs. Furthermore,
elevated leptin levels may potentially explain the well
established association between increased pain and female
sex or obesity. However, the causal relation between leptin
and joint pain needs to be confirmed in a longitudinal study.
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